Revenue
Margin
Demand
Guidance
Tone
Metrics cut 1
- UP legacy project completion deferred to FY28 (prior expectation: FY27 completion)
Event Participants
Executives
4
Aankur Patni, Indraneel Dutt, Nikisha Solanki, Vasant Naik
Analysts
9
Costa Bopana (Kamana Holdings), Deepak (Sundaram Mutual Fund), Norris Crasto (IMS), Pratik Kothari (Unique PMS), Rahul Kayan (Triton Investment Advisors), Richa Chaudhary (Electrum Capital), Sagar Parikh (Renaissance Investment Managers), Saket Kapoor (Kapoor & Co.), Surabhi Gupta (THB Asset Management)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Operating Income | ₹701 crores | +20% YoY; double-digit growth across all five segments |
| EBITDA | ₹32 crores | -49% YoY; legacy project overruns, ROHA ramp-up costs, geopolitical disruptions and input-cost inflation |
| EBIT Margin | 4.54% | Down sharply YoY; treatment solutions loss and specialty chemicals margin compression |
| Net Profit | ₹3 crores | PAT margin 0.44%; impacted by elevated costs and absence of prior-year FX gain |
| Order Backlog | ₹2,473 crores | As of June 2026; excludes ~$52M Hyundai order announced post-quarter; pipeline ₹9,777 crores |
Geographic & Segment Commentary
- Treatment Solutions: Revenue ₹210 crores (+14% YoY); EBIT loss of ₹17 crores on legacy project cost overruns. Dispatches to GCC resumed; focus on executing ₹2,473 crore backlog, selective bidding, and pivoting to advanced/emerging solutions (ultra-pure water, resource recovery).
- Industrial Products: Revenue ₹105 crores (+14% YoY); EBIT grew 145% to ~₹12.5 crores, margin 11.89% vs <6% a year ago. Membranes and standard plants drove the beat, supported by expanded Goa manufacturing and capacity investments.
- Life Cycle Services: Revenue ₹72 crores (+28% YoY); EBIT ₹7 crores (+22% YoY), margin 9.92% vs 10.5%. Scaling O&M, consumables, retrofits, BOO/rentals; PDO Oman 20-year concession highlights the recurring-revenue model (product/chemical profits booked in other segments).
- Specialty Chemicals: Revenue ₹230 crores (+21% YoY); EBIT ₹22 crores (-52% YoY). Drags: ROHA start-up costs (
6% impact), input-cost inflation, geopolitical freight/invoicing disruption, and absence of prior-year FX gain (3-4%). - Consumer Products: Revenue ₹112 crores (+33% YoY); loss narrowed to ₹0.34 crores from ₹0.45 crores. Growth broad-based (purifiers, softeners, wellness, OTG); Nepal expansion on track; targeting FY27 breakeven.
Company-Specific & Strategic Commentary
- Segment Reclassification: Engineering split into Treatment Solutions, Industrial Products and Life Cycle Services; chemicals renamed Specialty Chemicals. Reclassification reveals ~60% of consolidated revenue from products/chemicals/services vs ~40% treatment solutions. No corporate action planned—purely a transparency initiative.
- ROHA Resin Expansion (5x): Combined ROHA + Ankleshwar resin capacity targeted at 5x historical levels; ROHA is India's first non-solvent resin plant, commissioned and stabilizing, with an integrated spent catalyst recovery line (global first). Aspiration: ~10% of global resin volume share.
- Pharma Resin Scale-up: Ankleshwar FDA-approved pharma resin facility to expand 6x within 12 months; third global supplier for this application; import-substitution play with light capex (IP/know-how led).
- Membrane & Industrial Scale-up: Goa to become India's only integrated full-range membrane manufacturer (RO/UF/NF/MF) via MANN+HUMMEL tie-up; second plant under construction; standard plant capacity raised across Hosur, Goa and Wada; industrial products business targeted for 3x growth.
- Global Decentralization & Certifications: WQA certification secured for North America (pre-requisite for resin sales there); regional leaders appointed for Americas (Sanjay Sapra), APAC and Middle East-Africa, with Europe hire in process. International revenue ~30% of total; Portugal/Iberia acquisition serves as gateway to Europe/North Africa.
- Order Momentum:
$52M (₹500+ crores) Hyundai order (post-quarter) is pure product supply on FOB Mumbai terms—less risky than EPC; PDO Oman 20-year O&M concession win; total pipeline ₹9,777 crores.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| ROHA Utilization | 25% in FY27 (first year) | Guidance maintained; first four months softer than expected; will revisit after Q2 FY27 |
| Consumer Products | Breakeven in FY27 | First milestone; 33% YoY growth; single-digit margin expansion to follow |
| Specialty Chemicals Revenue | ≥50% increase over next 2 years | From ~₹900 crore FY26 base; driven by ROHA utilization and asset turnover of ~2x on manufacturing capex |
| Pharma Resin Capacity | 6x expansion within 12 months | FDA-approved plant; IP-led, light capex; third global player |
| Legacy Projects | Significant completion of non-UP legacy in FY27; UP project spills to FY28 | UP tied to government fund flows; company will not increase receivable exposure |
| Treatment Solutions Margins | Recovery in medium term | Via selective bidding, advanced/emerging solutions and Hyundai-type less-risky supply orders |
Risks & Constraints
| Risk | Context |
|---|---|
| UP Legacy Project | Unexecuted portion ~11% of ₹2,473 crore order backlog; government funding constrained. Receivables exposure flat; execution calibrated to fund inflows; likely extends into FY28. |
| Geopolitical Disruption | West Asia crisis disrupted GCC dispatches and invoicing. Hyundai order routes via Strait of Hormuz but FOB Mumbai terms transfer risk at Mumbai port. |
| Input Cost Inflation | Petrochemical monomers/amines spiked sharply; price pass-through lags. Crude softening ($100+ to ~$80) should gradually relieve input costs if sustained. |
| ROHA Ramp-up | Utilization below plan in first four months; 25% FY27 target depends on H2 acceleration, with significant volumes earmarked for North America. |
| Consumer Profitability | Segment still loss-making at ~₹350-400 crore annual scale; FY27 breakeven hinges on sustaining 30%+ growth and cost discipline. |
Q&A Highlights
Reclassification Rationale & Structure
- Question: Why reclassify, and is there any planned corporate action such as separate listing? (Pratik Kothari, Unique PMS)
- Answer: The old engineering segment obscured the products, services and projects mix. Reclassification shows ~60% of revenue from products/chemicals/services vs ~40% treatment solutions. No listing or corporate action planned—objective is transparency on investments made. (Indraneel Dutt)
ROHA Capacity Scope & Global Aspiration
- Question: Does the 5x resin capacity uplift refer to one product, and how does it reconcile with ~₹500 crores of resin revenue in FY26? (Pratik Kothari / Sunil Kothari, Unique PMS)
- Answer: 5x refers to total combined ROHA + Ankleshwar resin capacity, not a single product. Management aspires to ~10% of global resin volume. No resin/pharma/specialty revenue breakup provided. (Indraneel Dutt)
Specialty Chemicals Margin Bridge
- Question: What explains the ~15pp YoY margin compression in chemicals, and how much is from ROHA? (Sunil Kothari, Unique PMS)
- Answer: ROHA adds ~6% drag at segment level; ~3-4% from absence of prior-year FX gain; remainder from input-cost inflation and lagged price pass-through. If crude remains soft, some margin should be recovered in FY27. (Vasant Naik)
Treatment Solutions Profitability Path
- Question: EBIT fell from ₹60 crores to ₹27 crores over five years on ~₹1,100 crore revenue—when do margins return to 10-11%? (Costa Bopana, Kamana Holdings; Sagar Parikh, Renaissance)
- Answer: Legacy projects are still in execution; no quick fix. Company is selective on bids, winning better-profile orders (Hyundai, Middle East), and shifting toward high-tech advanced/emerging solutions (lithium extraction, PFAS destruction, green hydrogen, semiconductor ultra-pure water) where competition is limited. Medium-term margin improvement expected over short-term volume. (Indraneel Dutt)
UP Legacy Project Status
- Question: Is the UP project closing this FY, and what is the unexecuted portion? (Norris Crasto, IMS; Saket Kapoor, Kapoor & Co.)
- Answer: Unexecuted portion is ~11% of the ₹2,473 crore backlog (June 2026). Project is fully mobilized but constrained by government fund flows; funds are trickling in but closure is unlikely in FY27—will spill into FY28. Receivables exposure kept flat. A separate large legacy project (besides UP) has significant completion targeted in FY27. (Indraneel Dutt, Vasant Naik)
ROHA Utilization & WQA Certification
- Question: Is the 25% first-year utilization guidance achievable, and has WQA certification started contributing to revenue? (Richa Chaudhary, Electrum; Norris Crasto, IMS)
- Answer: Guidance held; first four months softer than expected, revisit post-Q2. WQA is a prerequisite for resin sales in the Americas; a significant portion of ROHA volumes is earmarked for North America. No revenue quantum shared. (Indraneel Dutt)
Consumer Breakeven Scale & Margin Target
- Question: At ₹350-400 crore annual scale, when does consumer products break even and what is the optimal margin? (Richa Chaudhary, Electrum)
- Answer: FY27 breakeven is the first target; margin guidance will follow once that milestone is reached. (Indraneel Dutt)
Raw Material & Crude Softening Impact
- Question: With crude at ~$80 vs $100+, how will input costs (monomers, amines) trend? (Norris Crasto, IMS)
- Answer: Directionally positive, but geopolitical volatility keeps prices fluid. Cost increases are being passed on with a lag; benefits should accrue over coming quarters if crude stays soft. (Indraneel Dutt)
Life Cycle Services & Working Capital
- Question: Will services growth structurally improve working capital velocity and FCF versus EPC? (Rahul Kayan, Triton)
- Answer: Yes—the pivot to O&M, consumables, rentals and concessions is less capital-intensive. BOO/BOT models carry development capex, so deployments will be selective and asset-light. Stated services margin (~10%) understates true profitability because product/chemical profits sit in other segments. (Indraneel Dutt)
Hyundai Contract & Geopolitical Exposure
- Question: With the Iraq/Gulf-linked Hyundai order, is there delivery or deferral risk? (Norris Crasto, IMS)
- Answer: Contract is FOB Mumbai—Ion Exchange's obligation ends at Mumbai port; no transport risk assumed. Kickoff meetings ongoing; no anticipated delay. The order is pure product supply, less risky than EPC. (Indraneel Dutt, Vasant Naik)
Key Takeaway
Ion Exchange's Q1 FY27 consolidated revenue rose 20% YoY to ₹701 crores, but EBITDA fell 49% to ₹32 crores and net profit was just ₹3 crores, as legacy projects (notably UP), ROHA ramp-up costs, geopolitical disruptions and input-cost inflation weighed on margins. The company introduced a five-segment framework—Treatment Solutions (₹210 crore revenue, -₹17 crore EBIT), Industrial Products (₹105 crores, 11.89% EBIT margin), Life Cycle Services (₹72 crores, +28%), Specialty Chemicals (₹230 crores, +21%) and Consumer Products (₹112 crores, +33%)—to surface structural growth. Strategic catalysts include the 5x resin capacity expansion targeting ~10% global share, 6x pharma-resin scale-up, integrated membrane manufacturing in Goa, WQA certification for North America and a ~$52M Hyundai product-supply order. Management maintains the 25% ROHA utilization target for FY27, expects consumer breakeven this year and significant completion of non-UP legacy projects, while the UP project is expected to spill into FY28; watchpoints are UP fund flows, ROHA ramp-up and crude-linked input costs.